Drug Trial Radar · NCT07474792
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Mar 19, 2026
Primary completion
Oct 2027
Study completion Apr 2029
Sponsor
- Lead sponsor
- Oruka Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
ORKA-002Drug
ORKA-002 administered by subcutaneous (SC) injection
PlaceboOther
Placebo administered by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16Time frame: Week 16
- Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse events (TEAEs) and TEAEs of of Special Interest (TEAESIs)Time frame: Day 1 through Week 48
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
Oruka Therapeutics Investigative Site
Birmingham, Alabama
Oruka Therapeutics Investigative Site
Phoenix, Arizona
Oruka Therapeutics Investigative Site
Fountain Valley, California
Oruka Therapeutics Investigative Site
Los Angeles, California
Oruka Therapeutics Investigative Site
San Diego, California
Oruka Therapeutics Investigative Site
Santa Ana, California
Oruka Therapeutics Investigative Site
Santa Monica, California
Oruka Therapeutics Investigative Site
Cromwell, Connecticut
Oruka Therapeutics Investigative Site
Miami, Florida
Oruka Therapeutics Investigative Site
Rolling Meadows, Illinois
Oruka Therapeutics Investigative Site
Boston, Massachusetts
Oruka Therapeutics Investigative Site
Milford, Massachusetts
Oruka Therapeutics Investigative Site
Ann Arbor, Michigan
Oruka Therapeutics Investigative Site
Detroit, Michigan
Oruka Therapeutics Investigative Site
Warren, Michigan
Oruka Therapeutics Investigative Site
New Brighton, Minnesota
Oruka Therapeutics Investigative Site
Omaha, Nebraska
Oruka Therapeutics Investigative Site
Elmhurst, New York
Oruka Therapeutics Investigative Site
New York, New York
Oruka Therapeutics Investigative Site
Wilmington, North Carolina
Oruka Therapeutics Investigative Site
Bexley, Ohio
Oruka Therapeutics Investigative Site
Portland, Oregon
Oruka Therapeutics Investigative Site
Warrenton, Oregon
Oruka Therapeutics Investigative Site
Charleston, South Carolina
Oruka Therapeutics Investigative Site
Dallas, Texas
Oruka Therapeutics Investigative Site
Dallas, Texas
Oruka Therapeutics Investigative Site
Houston, Texas
Oruka Therapeutics Investigative Site
Webster, Texas
Oruka Therapeutics Investigative Site
Mill Creek, Washington
Oruka Therapeutics Investigative Site
Edmonton, Alberta, Canada
Oruka Therapeutics Investigative Site
Edmonton, Alberta, Canada
Oruka Therapeutics Investigative Site
Surrey, British Columbia, Canada
Oruka Therapeutics Investigative Site
Barrie, Ontario, Canada
Oruka Therapeutics Investigative Site
London, Ontario, Canada
Oruka Therapeutics Investigative Site
North Bay, Ontario, Canada
Oruka Therapeutics Investigative Site
Peterborough, Ontario, Canada
Oruka Therapeutics Investigative Site
Toronto, Ontario, Canada
Oruka Therapeutics Investigative Site
Toronto, Ontario, Canada
Oruka Therapeutics Investigative Site
Waterloo, Ontario, Canada
Oruka Therapeutics Investigative Site
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.